Soleno Therapeutics Inc

SLNO remains in an early Stage 1 consolidation with its 9/20 EMAs repaired and supporting price. Medium-term directional asymmetry is bullish, driven by multiple continuation patterns signaling demand dominance. However, price is extended and overbought with exhaustion visible in RSI and options. Execution should be deferred until a shallow pullback into the rising EMA cluster emerges to confirm support before engaging.

• ↑Q4 net revenue $91.7M (+40% sequential) and FY25 sales of $190.4M
• ↑1,250 patient start forms (~12.5% addressable US market) with 859 active patients
• ↓Lag from patient start forms to active dosing may pressure quarterly revenue